The Food and Drug Administration (FDA) approved pembrolizumab for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation or metastatic...
Original Article: FDA expands pembrolizumab indication for first-line treatment of NSCLC